Clinical significance of reduced SFRP1 expression in acute myeloid leukemia. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: An, Cui; Guo, Hong; Wen, Xiang-mei; Tang, Chun-yan; Yang, Jing; Zhu, Xiao-wen; Yin, Jia-yu; Liu, Qing; Ma, Ji-chun; Deng, Zhao-qun; Lin, Jiang; Qian, Jun
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 7(2015:Jul.)
• Page Start: 2056
• Page End: 2060
• Publication Date: 2015-07
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.977883
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Deregulation of secreted frizzled-related protein 1 (<italic>SFRP1</italic>) has been found in many types of cancer. However, the pattern of <italic>SFRP1</italic> expression in acute myeloid leukemia (AML) is still unclear. This study determined <italic>SFRP1</italic> expression in patients with AML. <italic>SFRP1</italic> expression was decreased markedly in patients with AML compared to controls (<italic>p</italic> &lt; 0.001). White blood cell (WBC) counts increased as <italic>SFRP1</italic> expression decreased in AML (<italic>p</italic> = 0.016). Patients with low <italic>SFRP1</italic> expression showed a different distribution of French–American–British (FAB) subtypes M1/M2/M3 from those with high <italic>SFRP1</italic> expression (<italic>p</italic> = 0.031). <italic>NPM1</italic> mutation was mainly observed in patients with low <italic>SFRP1</italic> expression (<italic>p</italic> = 0.011). There was a weak trend that patients with AML with low <italic>SFRP1</italic> expression had shorter overall survival (OS) than those with high <italic>SFRP1</italic> expression (<italic>p</italic> = 0.103). Our results indicate that reduced <italic>SFRP1</italic> expression is found more frequently in the less well-differentiated subgroups of AML and is associated with <italic>NPM1</italic> mutation in AML.</p> </abstract>